Nesiritid acetat CAS:114471-18-0

Nesiritid (Natrecor) je rekombinantna oblika 32 aminokislinski humani natriuretični peptid tipa B, ki ga običajno proizvaja ventrikularni miokard. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldoesterone system, stimulira ciklični gvanozin monofosfat, vodi do sprostitve gladkih mišičnih celic.

Neseritide was believed initially to be beneficial for acute decompensated congestive heart failure. Za ta namen je prejel odobritev ameriške uprave za hrano in zdravila leta 2001 po začetni neodobritvi. V juliju 2011 the results of the largest study so far for nesiritide was published in The New England Journal of Medicine; it showed that nesiritide was not associated with a change in mortality or re-hospitalizations.

Mainly has a strong angiotensin II vasoconstriction and increase in blood pressure. The mechanism is: 1. So that the body arteriole smooth muscle contraction, increased peripheral resistance; 2. So increase the release of adrenal aldosterone, causing sodium retention, increased blood volume; 3. Directly contribute to renal tubular sodium and water reabsorption; 4. So the brain central nervous sympathetic vasoconstrictor activity, causing increased peripheral vascular resistance; 5. Stimulate the adrenal medulla to release epinephrine and norepinephrine.